Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,085 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07294040Recruiting
Low blood pressure after anesthesia in older cancer surgery patients
This study looks at what causes low blood pressure after anesthesia starts in older patients with cancer who are having surgery. It may help doctors prevent complications.
Ankara, AnkaraAges 65 years+ - NCT07291063Recruiting
Immunotherapy plus chemo for advanced bile duct or gallbladder cancer
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07295821RecruitingPhase 2
Osimertinib for stage III lung cancer patients who can't have chemo
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
BeijingAges 18 years+ - NCT06774989Recruiting
Drug level monitoring in metastatic melanoma treatment
This trial checks how much of two drugs, encorafenib and binimetinib, remain in your blood while treating advanced melanoma that cannot be removed by surgery. The goal is to learn if drug levels affect how well the treatment works.
Boulogne-BillancourtAges 18 years+ - NCT06757244RecruitingPhase 2
Dovipa: Immunotherapy and vitamin D with chemo for advanced pancreatic cancer
This trial tests whether combining the immunotherapy dostarlimab with vitamin D3 and standard chemotherapy (mFOLFIRINOX) can help people with stage IV pancreatic cancer. It aims to see if this new approach is safe and effective.
MarseilleAges 18–75 - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT07284121Recruiting
Patient satisfaction and safety of Atezolizumab in routine care
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
KremsAges 18 years+ - NCT07286331RecruitingPhase 3
New drug vs chemo for advanced endometrial cancer
This trial tests a new drug (mocertatug rezetecan) compared to standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. It may help if your tumor has a protein called B7-H4.
Birmingham, AlabamaAges 18 years+ - NCT07286149RecruitingPhase 1/Phase 2
Study of MK-1084 plus other treatments for lung cancer
This trial tests a new drug (MK-1084) combined with other treatments for people with a specific type of advanced lung cancer (non-small cell, non-squamous) that has a KRAS G12C mutation. It is for those whose cancer has worsened after prior immunotherapy and chemotherapy.
Clermont, FloridaAges 18 years+ - NCT07282912RecruitingPhase 2
Extra treatment for certain digestive cancers with undetectable ctDNA
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
New Haven, ConnecticutAges 18–80 - NCT07277270RecruitingPhase 1
Study of a new drug with standard treatments for advanced solid tumors
This trial tests a new investigational drug called GSK5764227 when given along with standard cancer treatments or other drugs for people with advanced colorectal or prostate cancer that has spread and cannot be removed by surgery.
Reunion, FloridaAges 18 years+ - NCT07276373RecruitingPhase 1/Phase 2
Nenocorilant with nivolumab for advanced solid tumors
This trial tests a new drug called nenocorilant combined with nivolumab (an immunotherapy) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07276529Recruiting
Magnet procedure safety trial for colon surgery patients
This trial tests a new magnet device to connect sections of the colon after surgery. It may be an option for people who need part of their colon removed and are otherwise in good health.
Orlando, FloridaAges 22 years+ - NCT07274085RecruitingPhase 1
Study of HDM2017 for advanced solid tumors
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT03899428RecruitingPhase 2
Immune therapy versus targeted therapy for advanced liver cancer
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hong Kong, Hong Kong SARAges 18 years+ - NCT06314087RecruitingPhase 2
Personalized cancer vaccine with radiation therapy
This trial tests a personalized cancer vaccine combined with a special type of radiation therapy for people with advanced or recurrent cancers that no longer respond to standard treatments. The goal is to help your immune system better recognize and attack your cancer.
Shenzhen, GuangdongAges 18–80 - NCT07272512RecruitingPhase 4
Surufatinib for advanced neuroendocrine tumors
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
ShanghaiAges 18 years+ - NCT07276139Recruiting
Heart device experience and outcomes study
This study collects information from people who have a heart device (like a pacemaker) to learn how these devices work in real life and how they affect patients. By joining, you help doctors improve care for future patients.
Canberra, Australian Capital TerritoryAges 18 years+ - NCT07273708Recruiting
Immune cell study in liver cancer patients on immunotherapy
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Pavia, LombardyAges 18–90 - NCT06891742RecruitingPhase 1
A study of a new cell therapy for advanced liver cancer
This trial tests a new treatment called OriC902 for people with advanced liver cancer (HCC) that has not responded to standard therapies. The treatment uses special immune cells designed to target a protein called GPC3 found on cancer cells. The goal is to see if this approach can help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18–75 - NCT06641713Recruiting
Comparing two liver cancer treatments for large tumors
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
Beijing, Beijing MunicipalityAges 18–75 - NCT06712511Recruiting
Coffee's effect on energy and caffeine breakdown
This study looks at how coffee affects your body's energy use and how quickly you process caffeine. It may help explain why coffee affects people differently.
Shenzhen, GuangdongAges 18–40 - NCT07265622RecruitingPhase 1/Phase 2
Study of 7MW4911 for advanced solid tumors
This trial tests a new drug called 7MW4911 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a tumor that expresses a certain protein (CDH17).
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,085 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.